Non-Small Cell Lung Cancer (NSCLC) Harboring EGFR Mutations (EGFR-m) and Breast Cancer (BC): A Retrospective Analysis

被引：0
|
作者：
Moran, Teresa [1 ]
Quiroga, Vanesa [1 ]
Carcereny, Enric [1 ]
Cirauqui, Beatriz [1 ]
Margeli, Mireia [1 ]
Vila, Laia [1 ]
De Los, Maria [1 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Med Oncol, Badalona, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
EGFR mutations; Breast Cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MINI13.13
引用
收藏
页码：S310 / S311
页数：2
相关论文
共 50 条
  • [31] A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells
    Molina-Vila, Miguel A.
    Bertran-Alamillo, Jordi
    Reguart, Noemi
    Taron, Miquel
    Castella, Eva
    Llatjos, Mariona
    Costa, Carlota
    Mayo, Clara
    Pradas, Anna
    Queralt, Cristina
    Botia, Monica
    Perez-Cano, Maria
    Carrasco, Esther
    Tomas, Mireia
    Mate, Jose Luis
    Moran, Teresa
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (11) : 1224 - 1235
  • [32] Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain
    Rosell, Rafael
    Moran, Teresa
    Carcereny, Enric
    Quiroga, Vanessa
    Angel Molina, Miguel
    Costa, Carlota
    Benlloch, Susana
    Taron, Miquel
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2010, 12 (02) : 75 - 80
  • [33] Efficacy and safety of immunotherapy in EGFR-mutant advanced non-small cell lung cancer: A retrospective study
    Tu, Tingting
    Li, Yang
    Liu, Ying
    Jiang, Lifeng
    ASIAN JOURNAL OF SURGERY, 2023, 46 (08) : 3275 - 3277
  • [34] A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
    Russo, Alessandro
    Franchina, Tindara
    Ricciardi, Giuseppina Rosaria Rita
    Picone, Antonio
    Ferraro, Giuseppa
    Zanghi, Mariangela
    Toscano, Giuseppe
    Giordano, Antonio
    Adamo, Vincenzo
    ONCOTARGET, 2015, 6 (29) : 26814 - 26825
  • [35] Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
    Wang, Xiaochun
    Goldstein, David
    Crowe, Philip J.
    Yang, Jia-Lin
    ONCOTARGETS AND THERAPY, 2016, 9 : 5461 - 5473
  • [36] Managing Acquired Resistance in EGFR-Mutated Non-Small Cell Lung Cancer
    Forde, Patrick M.
    Ettinger, David S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 528 - 532
  • [37] Plasma EGFR mutation testing in non-small cell lung cancer: A value proposition
    Oellerich, Michael
    Christenson, Robert H.
    Beck, Julia
    Walson, Philip D.
    CLINICA CHIMICA ACTA, 2019, 495 : 481 - 486
  • [38] EXTENDED MUTATION PROFILING OF THE EGFR SIGNALLING PATHWAY IN NON-SMALL CELL LUNG CANCER SENT FOR EGFR MUTATION TESTING
    Do, Hongdo
    Solomon, Ben
    Fox, Stephen B.
    Dobrovic, Alexander
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1049 - S1049
  • [39] Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations
    Masuda, T.
    Imai, H.
    Kuwako, T.
    Miura, Y.
    Yoshino, R.
    Kaira, K.
    Shimizu, K.
    Sunaga, N.
    Tomizawa, Y.
    Ishihara, S.
    Mogi, A.
    Hisada, T.
    Minato, K.
    Takise, A.
    Saito, R.
    Yamada, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (09) : 702 - 709
  • [40] Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
    Chen, Dan
    Song, Zhengbo
    Cheng, Guoping
    ONCOTARGETS AND THERAPY, 2016, 9 : 4181 - 4186
12345